Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment

Breast Cancer Research

Table 2 Description of selected characteristics in subjects

	PMD reduction ≤10%	PMD reduction >10%	P
	n = 247	n = 31
Baseline characteristics
Age (years)	63.8 ± 6.2	61.5 ± 5.9	0.05
BMI (kg/m²)	25.4 ± 3.7	24.1 ± 4	0.02
HRT ever			0.10
No	106 (42.9)	8 (25.8)
Yes	141 (57.1)	23 (74.2)
Baseline PMD	14.7 ± 9.5	32 ± 9.1	<0.001
Time between mammograms (years)	1.9 ± 0.6	2.0 ± 0.5	0.30
Tumor characteristics
ER status			0.15
Positive	167 (67.6)	26 (83.9)
Negative	29 (11.7)	1 (3.2)
Missing	51 (20.6)	4 (12.9)
Treatment
Chemotherapy			0.48
No	236 (95.5)	31 (100)
Yes	11 (4.5)	0 (0)
Radiotherapy			0.60
No	159 (64.4)	22 (71)
Yes	88 (35.6)	9 (29)
Tamoxifen (mg)
20	137 (55.5)	13 (41.9)	0.47
40	50 (20.2)	9 (29.0)
20 and 40	57 (23.1)	9 (29.0)
*Others	3 (1.2)	0 (0)

Description of selected characteristics in subjects with less than or greater than a 10% percent mammographic density (PMD) reduction, with P values for association. Categorical variables (frequencies (%)) were assessed for association using chi-squared tests, while continuous variables (means ± standard deviation (SD)) were assessed using Kruskal-Wallis tests. *One woman was prescribed an unknown dose of tamoxifen. Two women were prescribed tamoxifen citrate and two were prescribed toremifene, a chlorinated derivative of tamoxifen. HRT, hormone replacement therapy; BMI, body mass index; ER, estrogen receptor.

ISSN: 1465-542X